Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide

Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide

To develop CpG oligodeoxynucleotides (CpG ODNs) based therapy for prevention and treatment of severe acute respiratory syndrome (SARS), we selected a novel CpG ODN (BW001), which displays B-type CpG ODN structure feature at the 5' and A-type CpG ODN structure feature at the 3', and tested...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 118(2006), 2-3 vom: 30. Feb., Seite 180-7
1. Verfasser: Bao, Musheng (VerfasserIn)
Weitere Verfasser: Zhang, Yi, Wan, Min, Dai, Li, Hu, Xiaoping, Wu, Xiuli, Wang, Li, Deng, Ping, Wang, Junzhi, Chen, Jianzhu, Liu, Yongjun, Yu, Yongli, Wang, Liying
Format: Aufsatz
Sprache:English
Veröffentlicht: 2006
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Adjuvants, Immunologic Antiviral Agents CPG-oligonucleotide Oligodeoxyribonucleotides